Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Fan, Xuechun Lu, Xiaohui Wang, Yang Liu, Bo Guo, Yan Zhang, Wenying Zhang, Jing Nie, Kaichao Feng, Meixia Chen, Yajing Zhang, Yao Wang, Fengxia Shi, Xiaobing Fu, Hongli Zhu, Weidong Han
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2014/371087
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items